Version July 2025
| Name | Standard adult regimen¶ | Benefit for psoriatic arthritis |
| Biologic IL-23 inhibitors | ||
| Guselkumab | 100 mg given subcutaneously at weeks 0, 4, and then every 8 weeks | Yes |
| Risankizumab | 150 mg given subcutaneously at week 0 and week 4, then every 12 weeks | Yes |
| Tildrakizumab | 100 mg given subcutaneously at weeks 0 and 4 and then every 12 weeks | Under investigation |
| Biologic IL-17 inhibitors | ||
| Bimekizumab | 320 mg given subcutaneously every 4 weeks for the first 16 weeks, followed by 320 mg given every 8 weeks | Yes |
| Brodalumab | 210 mg given subcutaneously at weeks 0, 1, and 2 and then every 2 weeks. | YesΔ |
| Ixekizumab | 160 mg given subcutaneously at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12. Subsequently, 80 mg are given every 4 weeks. | Yes |
| Secukinumab | 300 mg given subcutaneously once weekly at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Doses of 150 mg are sufficient for some patients. | Yes |
| Biologic IL-12/23 inhibitor | ||
| Ustekinumab | For adults ≤100 kg: 45 mg given subcutaneously at weeks 0, 4, and every 12 weeks thereafter. For adults >100 kg: 90 mg dose given in the same regimen. | Yes |
| Biologic TNF-alpha inhibitors | ||
| Adalimumab | An initial 80 mg dose given subcutaneously, followed by 40 mg given every other week, beginning 1 week after the initial dose. | Yes |
| Certolizumab pegol | 400 mg given subcutaneously every other week. An optional regimen for patients who weigh ≤90 kg is 400 mg at weeks 0, 2, and 4, followed by 200 mg every other week. | Yes |
| Etanercept | 50 mg given subcutaneously twice weekly for the initial 3 months of therapy, followed by a 50 mg injection once weekly for maintenance therapy. | Yes |
| Infliximab | 5 mg/kg given via intravenous infusion at weeks 0, 2, and 6, followed by 5 mg/kg every 8 weeks thereafter. | Yes |
| Small molecule phosphodiesterase 4 inhibitor | ||
| Apremilast | 30 mg taken orally twice daily after initial dose titration (refer to UpToDate topic or Lexidrug monograph for titration schedule) | Yes |
| Small molecule tyrosine kinase 2 inhibitor | ||
| Deucravacitinib | 6 mg taken orally once daily | Under investigation |
| Other therapies | ||
| Acitretin | 25 mg every other day to 50 mg taken orally once daily | No |
| Cyclosporine (modified) | 2.5 to 5 mg/kg per day taken orally in 2 divided doses | No |
| Methotrexate | 7.5 to 25 mg taken orally or subcutaneously once weekly with folic acid supplementation | Yes |
IL: interleukin; TNF: tumor necrosis factor.
* Limited to drugs commercially available in the United States.
¶ Dose adjustments may be appropriate for some therapies based on patient comorbidities, organ function, or response to therapy.
Δ Use for psoriatic arthritis is off label in the United States.